Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

Mark A Ainsworth; Klaus Bendtzen; Jørn Brynskov

doi:10.1111/j.1572-0241.2007.01638.x

Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

Mark A Ainsworth, Klaus Bendtzen, Jørn Brynskov

156 Citations (Scopus)

Abstract

To investigate if the combined assessment of anti-infliximab antibodies (Ab) and the degree of TNF-alpha binding capacity (TNF-alpha-BC) afforded by infliximab may predict the response to infliximab treatment in patients with Crohn's disease (CD).

Original language	English
Journal	The American journal of gastroenterology
Volume	103
Issue number	4
Pages (from-to)	944-8
Number of pages	5
DOIs	https://doi.org/10.1111/j.1572-0241.2007.01638.x
Publication status	Published - 1 Apr 2008
Externally published	Yes

Access to Document

10.1111/j.1572-0241.2007.01638.x

Cite this

Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. / Ainsworth, Mark A; Bendtzen, Klaus; Brynskov, Jørn.
In: The American journal of gastroenterology, Vol. 103, No. 4, 01.04.2008, p. 944-8.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{044a91abb3a44af396648db73c4b77b8,

title = "Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease",

abstract = "To investigate if the combined assessment of anti-infliximab antibodies (Ab) and the degree of TNF-alpha binding capacity (TNF-alpha-BC) afforded by infliximab may predict the response to infliximab treatment in patients with Crohn's disease (CD).",

author = "Ainsworth, {Mark A} and Klaus Bendtzen and J{\o}rn Brynskov",

year = "2008",

month = apr,

day = "1",

doi = "10.1111/j.1572-0241.2007.01638.x",

language = "English",

volume = "103",

pages = "944--8",

journal = "The American journal of gastroenterology",

issn = "1572-0241",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

AU - Ainsworth, Mark A

AU - Bendtzen, Klaus

AU - Brynskov, Jørn

PY - 2008/4/1

Y1 - 2008/4/1

N2 - To investigate if the combined assessment of anti-infliximab antibodies (Ab) and the degree of TNF-alpha binding capacity (TNF-alpha-BC) afforded by infliximab may predict the response to infliximab treatment in patients with Crohn's disease (CD).

AB - To investigate if the combined assessment of anti-infliximab antibodies (Ab) and the degree of TNF-alpha binding capacity (TNF-alpha-BC) afforded by infliximab may predict the response to infliximab treatment in patients with Crohn's disease (CD).

U2 - 10.1111/j.1572-0241.2007.01638.x

DO - 10.1111/j.1572-0241.2007.01638.x

M3 - Journal article

C2 - 18028512

SN - 1572-0241

VL - 103

SP - 944

EP - 948

JO - The American journal of gastroenterology

JF - The American journal of gastroenterology

IS - 4

ER -

Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease

Abstract

Access to Document

Fingerprint

Cite this